Form 4: Ionis Pharmaceuticals Director Equity Grants Detailed

Allene M. Diaz, a Director at Ionis Pharmaceuticals, received stock options and restricted stock units on July 1, 2026, with specific vesting and deferral terms.

Summary

• Allene M. Diaz, a Director at Ionis Pharmaceuticals (IONS), was granted stock options and restricted stock units (RSUs) on July 1, 2026.
• The stock options have an exercise price of $79.19 and are exercisable starting July 1, 2027, with an expiration date of June 30, 2036.
• The grant includes 5,369 stock options and 2,301 RSUs.
• These grants are subject to the company's Non-Employee Director Compensation Policy, with adjustments to ensure annual equity compensation does not exceed $400,000 in grant date fair value for 2026.
• Both the stock options and RSUs vest 100% on the first anniversary of the grant date or the next annual stockholder meeting, whichever is earlier.
• The reporting person has elected to defer the delivery of shares from the RSUs until a later date, as defined by specific conditions related to separation from service or change in control.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it represents routine equity compensation for a director and does not provide new financial information or strategic updates.

Positives

• Director Allene M. Diaz received equity grants, indicating continued alignment with the company's performance.
• The grants are part of a structured compensation policy designed to manage director equity awards.
• Vesting schedules and deferral elections provide a long-term incentive structure.

Negatives

• The filing details equity grants, which represent potential future dilution for existing shareholders.
• The exercise price of the stock options ($79.19) is significantly higher than the current market price (as of the filing date, though not explicitly stated in the document, this is a common implication for options granted at a premium).

Risks

• The value of the stock options and RSUs is subject to market fluctuations and the company's future stock performance.
• The deferral election for RSUs introduces a risk that the ultimate value received by the director may differ significantly from the grant date valuation due to market changes over the deferral period.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding future financial performance. It solely details equity grants to a director.

Industry Context

StockSavvy.ai notes that equity grants to directors are a standard practice in the biopharmaceutical industry, used to attract and retain talent and align executive interests with shareholder value. The specific terms of these grants, including vesting and deferral, are typical for non-employee directors.

Corporate Governance

Related Party Transactions

• The grant of stock options and restricted stock units to Director Allene M. Diaz constitutes a related party transaction, as it involves compensation to a company insider.

Stakeholder Impact

• Shareholders: Potential for future dilution upon exercise of options or vesting/delivery of RSUs. The grants are part of a standard compensation structure designed to align director interests with long-term shareholder value.
• Employees: No direct impact mentioned.
• Management: Reinforces standard compensation practices for the board.
• Creditors: No direct impact mentioned.

Next Steps

• Vesting of stock options and RSUs according to the specified schedule.
• Potential exercise of stock options by the reporting person.
• Potential delivery of shares from RSUs based on deferral conditions being met.

Key Dates

Keywords

Ionis Pharmaceuticals, IONS, Form 4, SEC Filing, Director Compensation, Stock Options, Restricted Stock Units, Equity Grants, Beneficial Ownership, Allene M. Diaz